Atea Supports Bemnifosbuvir-Ruzasvir Combo for Hepatitis C at AASLD
15 Nov 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Q3 2024 Finacial Results
30 Oct 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals Updates Global Phase 3 SUNRISE-3 Trial Of Bemnifosbuvir
13 Sep 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals Publishes Data On Bemnifosbuvir`s Activation
28 Aug 2024 //
GLOBENEWSWIRE
Atea: Positive Initial Phase 2 Bemnifosbuvir+Ruzasvir Data In HCV At EASL
05 Jun 2024 //
GLOBENEWSWIRE
Atea Shows Bemnifosbuvir-Ruzasvir HCV Combo Potential At EASL
22 May 2024 //
GLOBENEWSWIRE
Atea`s Bemnifosbuvir Safety Data at ESCMID Global 2024
29 Apr 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals Completes Patient Enrollment for Phase 3 SUNRISE-3 Trial
27 Mar 2024 //
GLOBENEWSWIRE
Atea Pharma Presents Promising Bemnifosbuvir and Ruzasvir Combination Data
13 Nov 2023 //
GLOBENEWSWIRE
Atea to Present Bemnifosbuvir and Ruzasvir Data for Hepatitis C Virus
02 Nov 2023 //
GLOBENEWSWIRE
Atea Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir
25 Apr 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals announces results of bemnifosbuvir for Covid-19
15 Mar 2023 //
CLINICAL TRIALS ARENA
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19
08 Mar 2023 //
GLOBENEWSWIRE
Atea Reports Nonclinical AT-527 Toxicology Data at Society of Toxicology
28 Mar 2022 //
GLOBENEWSWIRE
Atea’s AT-527 Reduces Viral Replication in Hospitalized Patients with COVID-19
30 Jun 2021 //
GLOBENEWSWIRE